Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era
Navneet S. Majhail(Sarah Cannon), John E. Levine(Icahn School of Medicine at Mount Sinai), Willis H. Navarro(University of California, San Francisco), Steven M. Devine(National Marrow Donor Program), Galen E. Switzer(University of Pittsburgh), Brent R. Logan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Chatchada Karanes(Erasmus MC Cancer Institute), Eneida R. Nemecek(Oregon Health & Science University), Edward L. Snyder(Yale University), Ginna G. Laport(Stanford Blood Center), Pintip Chitphakdithai(National Marrow Donor Program), Susan Rossmann, Roberta King(University of Iowa), Robert J. Hartzman(National Marrow Donor Program), Dennis L. Confer(National Marrow Donor Program), Gregory A. Hale(Johns Hopkins University), J. Philip Miller(University of Minnesota)
Cited by 76
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
|Journal of Clinical Oncology|2001|898
Advancing Health Disparities Research Within the Health Care System: A Conceptual Framework
|American Journal of Public Health|2006|763
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age
|Blood|2001|701
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664